NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/11/2026 15:37
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization116.8 mln
Float6.35 mln
Earnings Date05/20/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
19.43
Transformational upside
Relative Strength
5
/ 100
Severely lagging
Debt / Equity
0.02
Debt-free
ROE
-154
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2019 and based in Berkeley Heights, New Jersey, Kalaris Therapeutics is a medical company focused on developing new treatments for serious eye diseases that affect the retina. Its lead drug candidate, TH103, targets abnormal blood vessel growth in the eye and is currently being tested in mid-stage clinical trials as a potential treatment for age-related macular degeneration and similar conditions. The company was previously known as Theia Therapeutics before adopting its current name in May 2024.
